Compare Orion Office REIT Inc (ONL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Orion Office REIT Inc trades at $2.11 (market cap $119.79M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 62.8× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.81% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 34 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ONL | SYRE | |
|---|---|---|
Market Cap | $119.79M | $7.52B |
Volume | 378,596 | 1,441,031 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $108.92 |
52-Week Low | $1.93 | $22.18 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $536.73M | $6.52B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.10, down 2.33% today, with a bearish technical signal from moving averages. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear mixed with low P/S (0.84) and P/B (0.19) ratios but negative profitability margins. Analyst consensus is evenly split between Buy and Hold ratings.
The outlook remains challenging due to ongoing revenue declines and negative margins, though the deep discount to book value and recent earnings beat offer potential upside. Key risks include high debt levels, weak office property demand, and sustained cash flow pressures. Investors should weigh the value proposition against fundamental weaknesses.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
